Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1503262
This article is part of the Research Topic Adapting Drug Repurposing to Drug Resistance in Cancer Volume II: Developing Synergistic Combinations View all 4 articles

Brigatinib Treatment in a Patient with Advanced NSCLC with XPO1-ALK Fusion: A Case Report

Provisionally accepted
Yang Zhang Yang Zhang Kejie Li Kejie Li *Can Wang Can Wang *Changlin Zou Changlin Zou *Meng Su Meng Su *
  • First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

The final, formatted version of the article will be published soon.

    Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.

    Keywords: XPO1-ALK, brigatinib, Lung Adenocarcinoma, targeted therapy, case report

    Received: 28 Sep 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Zhang, Li, Wang, Zou and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kejie Li, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
    Can Wang, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
    Changlin Zou, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
    Meng Su, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.